On February 25, temperature control is crucial in the field of aviation cold chain transportation, especially in the transportation of vaccines and biopharmaceuticals. CIMC, headquartered in Shenzhen, announced on the 25th that it had successfully developed the first RAP active temperature-controlled aviation box in China. It not only fills the gap in similar products in China, but also enables “heaven-earth linkage” full-process tracking to ensure that medicines do not lose the “cold chain”. For a long time, Chinese airlines have mainly relied on aviation boxes leased from abroad, which is costly. In 2020, Qingdao CIMC Special Refrigeration Equipment Co., Ltd. (hereinafter referred to as “CIMC Qingdao Refrigerated Special Box”), a subsidiary of CIMC, developed the first RKN active temperature-controlled aviation container in China, breaking the foreign monopoly in one fell swoop. The RKN air box is powered by a battery and uses a refrigeration unit to control the temperature inside ...
On February 25, the Hong Kong stock price of CanSino Biologics (06185.HK, share price of HK$37.35, market value of HK$9.2 billion) once soared by more than 15%. On the news front, the company issued an announcement the day before, saying that the adsorbed acellular pertussis (component) Haemophilus influenzae type b (combined)-ACYW135 group meningococcal (combined) combined vaccine (DTcP-Hib-MCV4) has been approved for drug clinical trials. This is a pentavalent vaccine that prevents multiple diseases at the same time. It has three components: the first Asian quadrivalent meningococcal conjugate vaccine “Manhaixin” that has been approved for marketing, the second is the adsorbed acellular diphtheria (component) pertussis combined vaccine for infants and young children in the phase III clinical stage, and the third is the Hib vaccine (Haemophilus influenzae type b vaccine) in the phase I clinical stage. It is worth noting that this is the first domestic pentavalent vaccine to reach the ...
Recently, the National Drug Administration Drug Evaluation Center (CDE) announced that the clinical trial application (IND) for the mRNA vaccine YKYY025 injection for the prevention of respiratory syncytial virus (RSV) submitted by Hangzhou Tianlong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yuekang Pharmaceutical, has been accepted. Prior to this, this vaccine had been approved for clinical trials by the US FDA at the beginning of this year. “Insight into and meeting clinical needs that have not yet been fully responded to have always been the core orientation and key path for our research and development work.” Yu Weishi, chairman of Yuekang Pharmaceutical Group, said. It is reported that in addition to RSV vaccines, Yuekang Pharmaceutical has obtained overseas clinical approval for a number of innovative drugs. On January 21, Yuekang Pharmaceutical’s independently developed mRNA vaccine YKYY026 injection for the prevention of herpes zoster was officially accepted by CDE. Since it ...
DeepSeek is penetrating into various industries. In February 2025, the domestic large model DeepSeek-R1 was fully open source and adapted to multiple fields, and AI medical care also entered a new stage of technology integration and industry reconstruction. Many companies including Aimi Vaccine, Hengrui Medicine, and Zhiyun Health announced that they are combining with AI large models such as DeepSeek. Take the recent announcement of Aimi Vaccine as an example. It stated that as a leading vaccine company in China, the group actively responded to the national “AI+” industrial development strategy and fully deployed access to the DeepSeek large model. However, the financial report of Aimi Vaccine shows that it has faced continuous losses in recent years. To what extent can DeepSeek reduce costs and increase efficiency? Many industry analysts consulted by Blue Whale Finance all said that overall, they are optimistic about the application of AI big models such ...
Recently, Shiyao Group announced that its subsidiary Shiyao Jushi has signed an exclusive authorization agreement with Radiance Biopharma for the antibody conjugate drug SYS6005. Since 2025, several pharmaceutical companies, including Xinda Biotechnology and Xiansheng Pharmaceutical, have signed large orders with potential amounts of up to 1 billion US dollars. Industry insiders believe that the overall progress of domestic new drug research and development is commendable, and Chinese pharmaceutical companies with strong research and development capabilities are expected to compete with foreign-funded enterprises in the global market. They are optimistic about the prospects of domestic new drug research and development and going global in 2025. Multiple products achieve overseas authorization According to the announcement from Shiyao Group, Shiyao Giant Stone has agreed to grant Radiance Biopharma exclusive authorization to develop and commercialize SYS6005 in the United States, European Union, United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, ...
On February 21, 2025, Boston Scientific (NYSE: BSX) announced that its fully funded subsidiary, American Medical Systems Europe B.V. (“AMS Europe”), has priced a total of 1.5 billion euros (approximately RMB 11.377 billion) in notes (a type of bond issuance). The funds obtained from this issuance, along with the company’s cash on hand, will be used for debt repayment, working capital, and potential future acquisitions. As of February 21st, Boston Scientific’s latest stock price is $104.49 per share, with a total market value of $154 billion, reaching its highest point since going public. 01. Issuing bonds worth billions, PFA’s performance skyrocketed by 172% The notes issued this time consist of two transactions, one with a total principal of 850 million euros and an interest rate of 3.000%, due in 2031; The other principal amount is 650 million euros, with an interest rate of 3.250%, due in 2034. The bill will ...
Recently, the National Medical Products Administration’s Device Review Center released the results of the special review application for innovative medical devices (No. 2 of 2025), intending to approve 9 medical devices to enter the innovation channel. 1. Peripheral arterial stent graft system: Jiangsu Pupeng Medical Technology Co., Ltd Pupeng Medical was established on December 16, 2019, and is a subsidiary of Jiangsu Zhenyi Medical Technology Co., Ltd. (hereinafter referred to as Zhenyi Medical). It is reported that Zhenyi Medical focuses on the cardiovascular disease field with extremely high mortality and disability rates, and the domestic market is still blank. Its business comprehensively covers multiple interventional treatment fields such as heart valves, peripheral and coronary arteries. It is the first platform enterprise to achieve one-stop innovative solutions for blood flow management on a global scale. In addition to the products that entered the innovation channel this time, Park Peng Medical also ...
As of 10:13 on February 20, 2025, the CSI Vaccine and Biotechnology Index rose strongly by 1.13%, with constituent stocks Yifang Biotech rising by 7.45%, Dizhe Pharmaceuticals rising by 6.93%, Shuanglu Pharmaceuticals rising by 4.37%, and Wanze Shares, Dongbao Bio and other stocks following suit. Bio-Vaccine ETF (562860) rose by 1.14%, and the intraday turnover has reached 6.5605 million yuan. In terms of scale, the scale of Bio-Vaccine ETF has increased by 3.2427 million yuan in the past week, achieving significant growth. It is worth noting that the valuation of the CSI Vaccine and Biotechnology Index tracked by the fund is at a historical low, with the latest price-to-book ratio PB being 2.95 times, which is lower than the index’s 83.43% of the past five years, and the valuation cost-effectiveness is outstanding. Data shows that as of January 27, 2025, the top ten weighted stocks in the CSI Vaccine and ...
On February 19, CSPC Pharmaceutical Group announced that its subsidiary CSPC Pharmaceutical Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Bio”) has reached an important agreement with Radiance Biopharma. According to the agreement, Radiance Biopharma will obtain the exclusive development and commercialization rights of Jushi Bio’s independently developed SYS6005 project in the United States, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia and Canada. Jushi Bio will receive a down payment of US$15 million, a development and regulatory milestone amount of US$150 million, a sales milestone amount of US$1.075 billion, and a certain percentage of sales revenue. SYS6005: An innovative ADC drug SYS6005 is a monoclonal antibody-drug conjugate (ADC) independently developed by Jushi Bio. It can bind to specific receptors on the surface of tumors, enter cells through endocytosis and release toxins to kill tumor cells. SYS6005 uses Jushi Bio’s ...
Recently, Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, submitted a marketing authorization application for HR19034 Eye Drops (Atropine Sulfate Eye Drops) to the National Medical Products Administration, which has been accepted. This product is mainly used to prevent and control the progression of myopia in children and adolescents. According to the Yaozhi Data global drug analysis system, Hengrui Medicine’s HR19034 project started clinical trials in April 2021. After completing the Phase I trial, the company immediately started Phase II/Phase III research. According to Hengrui’s announcement, the project will complete a three-year clinical trial in August 2024. Research data showed that HR19034 was superior to the control group in terms of the primary endpoint and demonstrated good safety and tolerability in children with myopia. The most common application of atropine in ophthalmology is mydriasis. Atropine sulfate at a concentration of 1% is usually used for fundus examination and eye examination ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.